A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) Clinical Trial

Official title:
a Single-arm, Open, Multicenter, Phase II Study to Investigator the Efficacy and Safety of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Status Recruiting

Clinical Trial Summary

this is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 monotherapy in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details

NCT number	NCT05241106
Study type	Interventional
Source	Tarapeutics Science Inc.
Contact	Yang Shu, MD. BS.
Phone	86-13918983465
Email	shuyang@tarapeutics.com
Status	Recruiting
Phase	Phase 2
Start date	September 29, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04113616` - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Recruiting	`NCT05241093` - A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Phase 2
Recruiting	`NCT02074839` - Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation	Phase 1
Terminated	`NCT05345938` - A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT03218683` - Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.	Phase 1